PRAX · NASDAQ · STOCK
Praxis Precision Medicines (PRAX) Stock Analysis
$308.97
52W $41.77 – $392.70
56/100
$8.72B
-24.2
2.78
Is PRAX Bullish or Bearish?
Bullish.
Innellis AI committee rates Praxis Precision Medicines, Inc. (PRAX) Buy with a composite score of 56/100
, based on 5 analysts with 60% agreement.
Last updated September 17, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +18.58 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -1.42 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The primary driver is news sentiment is positive (+0.50 across 2 articles, 14d). The main limiting factor is rsi at 19 is in oversold territory (could mean either capitulation or a bounce setup). The committee is constructive but not yet at full conviction.
Bull & Bear Case
Bull Case
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
- News sentiment is positive (+0.50 across 2 articles, 14d) — News
Bear Case
- Price-to-book of 8.4x prices in significant intangible value — Value
- ROE of only -43.0% -- cheap may mean cheap for a reason — Value
- RSI at 19 is in oversold territory (could mean either capitulation or a bounce setup) — Technical
- MACD histogram negative -- bearish momentum — Technical
- Price trading below the lower Bollinger Band -- stretched to the downside — Technical
- Bollinger bandwidth of 20.0% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of September 17, 2026
Overall Committee Score
56/100
Agreement
60%
Analysts
5
Conviction
Moderate
Sector Rank
Top 58%
of 192 Healthcare peers
Value Analyst
neutral
43
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− Price-to-book of 8.4x prices in significant intangible value
Technical Analyst
bearish
38
/ 100 · High confidence
Price action is deteriorating -- trend and/or momentum are working against this name
− RSI at 19 is in oversold territory (could mean either capitulation or a bounce setup)
Risk Analyst
bullish
62
/ 100 · Moderate confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
− Bollinger bandwidth of 20.0% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
74
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.50 across 2 articles, 14d)
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2514.55)
Investment Thesis Evolution
Committee score moved marginally from 56.4 to 56.4.
Comparing 2026-09-16 to 2026-09-17 (1 day apart).
Technical Analysis
RSI (14)
18.9
Oversold
MACD Histogram
-6.119
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Hh Hl
Support
$288.01
Resistance
$352.78
Bollinger %B
-0.10
Below Lower Band
Price vs Moving Averages
EMA 9
$338.13
Below
EMA 21
$346.36
Below
EMA 50
$340.95
Below
EMA 200
$291.47
Above
Fundamental Analysis
Valuation
40
Growth
61
Profitability
0
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-24.2×
P/B Ratio
6.80×
PEG Ratio
4.29
Dividend Yield
0.00%
52W High
$392.70
52W Low
$41.77
Quality & Growth
ROE
-3453.5%
ROA
-3233.4%
Gross Margin
0.0%
Operating Margin
0.0%
Revenue Growth YoY
—
Debt / Equity
0.00
AI Fundamental Assessment
P/E ratio of -24.2 (inexpensive relative to a 15-40x range); Price-to-book of 6.8x; PEG ratio of 4.3 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -34.5%; Return on assets of -32.3%; Net margin of 0.0%; Gross margin of 0.0%; Current ratio of 15.73 (healthy short-term liquidity); Debt-to-equity of 0.00; Free cash flow per share is negative (-10.50); Most recent quarter beat estimates by 23.1%; 2 consecutive earnings beats; EPS growth roughly steady (+8.6% -> +10.3% QoQ); Analyst estimates falling over recent quarters
Get the Full PRAX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →